| Date Filed | Type | Description |
| 10/10/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/05/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 10% stake in Madrigal Pharmaceuticals, Inc. |
| 08/17/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/10/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 2.2% stake in Mereo BioPharma Group plc |
| 08/10/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 0% stake in Verastem, Inc. |
| 08/08/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 8.4% stake in Madrigal Pharmaceuticals, Inc. |
| 07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/28/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 10% stake in IGM Biosciences, Inc. |
| 06/12/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 8% stake in Verastem, Inc. |
| 05/24/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 26.5% stake in ACADIA Pharmaceuticals Inc. |
| 05/24/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 19.5% stake in Prelude Therapeutics Incorporated |
| 05/05/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/05/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 05/03/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/15/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 16.4% stake in Incyte Corporation |
| 03/13/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 25.3% stake in Seagen Inc. |
| 03/10/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 66.2% stake in Talis Biomedical Corporation |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.1% stake in Akero Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7.5% stake in Aravive, Inc. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 2.3% stake in Surrozen, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 6.6% stake in HOOKIPA Pharma Inc. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 6.8% stake in Opthea Limited |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 10% stake in Kala Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.4% stake in 2seventy bio, Inc. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 13.5% stake in Verastem, Inc. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 10% stake in BioCryst Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 5.9% stake in Zymeworks Inc. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 9.1% stake in Cerus Corporation |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 0% stake in Merus N.V. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 10% stake in Mereo BioPharma Group plc |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 9.9% stake in Achilles Therapeutics plc |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 9.9% stake in Aeglea BioTherapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 8.7% stake in Ascendis Pharma A/S |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 8% stake in Aerovate Therapeutics, Inc. |
|